Influenza vaccine

Development of scalable downstream processing platform for HEK293SF cell-based influenza vaccine production

More than half a million people die every year from complications of seasonal influenza, and vaccination stands as the most effective method to prevent and limit outbreaks of the disease. Constant vaccine development based on emerging strains and …

Recent advances and current challenges in process intensification of cell culture-based influenza virus vaccine manufacturing

Abstract Every year, millions of people are infected by the influenza virus around the world, which results in more than half a million deaths, particularly among the more vulnerable population. Since vaccination is the most efficient method of …

Characterization of influenza H1N1 Gag virus-like particles and extracellular vesicles co-produced in HEK-293SF

One of the concerns associated with the use of influenza virus-like particles (VLPs) as vaccine candidate or delivery system is their heterogeneous composition. Enveloped VLPs take up the host cell membrane at the budding site carrying out not only …